We serve Chemical Name:4-Aminobenzylamine CAS:4403-71-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Aminobenzylamine
CAS.NO:4403-71-8
Synonyms:4-(Aminomethyl)aniline;MFCD00075513;α-Amino-p-toluidine
Molecular Formula:C7H10N2
Molecular Weight:122.16800
HS Code:2921590090
Physical and Chemical Properties:
Melting point:37 °C
Boiling point:101 °C0.05 mm Hg(lit.)
Density:1.078 g/mL at 25 °C(lit.)
Index of Refraction:n20/D 1.61(lit.)
PSA:52.04000
Exact Mass:122.08400
LogP:2.00900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3259 8/PG 2
Packing Group:III
Contact us for information like 4-(Aminomethyl)aniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,α-Amino-p-toluidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(Aminomethyl)aniline Use and application,MFCD00075513 technical grade,usp/ep/jp grade.
Related News: Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 4-Aminobenzylamine manufacturer It is delivered to hospitals and pharmacies until it reaches the patient. 4-Aminobenzylamine supplier Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 4-Aminobenzylamine vendor ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� 4-Aminobenzylamine factory Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma.
